重组耻垢分枝杆菌对小鼠膀胱癌的抑癌效应  

Anti-tumor effect of recombinant Mycobacteria smegmatis on syngeneic mice bearing bladder cancer

作　　者：姚建忠[1] 刘齐贵[2] 李铁军[2] 靳风烁[1] 

机构地区：[1]第三军医大学大坪医院泌尿外科野战外科研究所,重庆400042 [2]解放军昆明总医院泌尿外科医务部,云南昆明650032

出　　处：《中国癌症杂志》2007年第10期792-795,共4页China Oncology

摘　　要：背景与目的:BCG膀胱灌注是治疗膀胱肿瘤防止其复发最有效的方法之一,但部分患者疗效差、且有一定副作用。研究新的分枝杆菌菌株将可能进一步降低BCG副作用,提高疗效。本研究探讨重组耻垢分枝杆菌对小鼠膀胱癌的抑癌效应。方法:采用T739可移植性膀胱癌模型,于移植瘤处局部注射重组耻垢分枝杆菌,并用耻垢分枝杆菌、卡介苗(BCG)和磷酸盐缓冲液(PBS)作对照,观察治疗后各组小鼠的肿瘤重量及其存活期。结果:重组耻垢分枝杆菌治疗组小鼠肿瘤瘤重(3.0±1.6)g,显著低于PBS组(6.8±1.3)g(P<0.01),而与BCG组(3.2±1.2)g相比,差异无显著性(P>0.05),抑瘤率为55.95%;重组耻垢分枝杆菌治疗组小鼠存活天数为(30.4±2.5)d,显著长于PBS组(23.2±2.2)d(P<0.05),与BCG组的(29.7±3.2)d相比,差异无显著性(P>0.05),存活延长率为31.23%。同时免疫组化分析表明重组耻垢分枝杆菌能增加肿瘤组织内CD3、CD4、CD8、CD56的表达。结论:重组耻垢分枝杆菌对小鼠膀胱癌具有抑制作用,并能延长膀胱癌荷瘤鼠的生存期。Background. and purpose： Intravesical instillation of BCG is one of the most effective treatment and recurrence prevention approach for bladder cancer, but the therapy is not well set up because of side effects and the efficacy. This study was to investigate whether recombinant Mycobacteria smegmatis will enhance the treatment effect and reduce complications on syngenic mice bearing bladder cancer. Methods： With the subcutaneous xenograft tumor model in T739 mice, BTT739 bladder transitional cell carcinoma were implanted in syngeneic mice, recombinant Mycobacteria smegmatis was locally injected to the mice at the site of implanting tumor as the trial group; BCG and phosphate buffered saline were injected to the mice as control groups. The weight of tumor and the survival period were recorded after treatment. Results： The aver age weight of trial group was （ 3.0 ± 1.6） g and significantly lower than that of phosphate buffered saline group （ 6.8 ± 1.3） g（ P 〈 0.01）, but there was no significant difference with BCG group（ 3.2 ± 1.2） g （ P 〉 0.05）, and the tumor inhibition rate of recombinant Mycobacteria smegmatis group was 55.95%. The average survival period of recombinant Mycobacteria smegmatis group was （ 30.4 ± 2.5） clays and significantly longer than that of phosphate buffered saline group（ 23.2 ± 2.2） d （ P 〈 0.05）, but there was no significant difference compared with BCG group（29.7 ± 3.2） days （ P 〉 0.05）. The survival prolongation rate of recombinant Mycobacteria smegmatis group was 31.23%. Histopathological examination revealed significantly increased immunocompetent cell numbers with CD3, CD4, CD8, CD56 phenotype in the trial animals. Conclusions： The resuhs indicate that recombinant Mycobacteria smegmatis has an obvious anti-tumor effect on T739 mice bearing bladder cancer and can prolong its survival period.

关 键 词：耻垢分枝杆菌 膀胱肿瘤 抑癌效应 

分 类 号：R730.54[医药卫生—肿瘤]